PT  - JOURNAL ARTICLE
AU  - ZSUZSANNA SCHELZ
AU  - MARTA MARTINS
AU  - ANA MARTINS
AU  - MIGUEL VIVEIROS
AU  - JOSEPH MOLNAR
AU  - LEONARD AMARAL
TI  - Elimination of Plasmids by SILA Compounds that Inhibit Efflux Pumps of Bacteria and Cancer Cells
DP  - 2007 Jul 01
TA  - In Vivo
PG  - 635--639
VI  - 21
IP  - 4
4099  - http://iv.iiarjournals.org/content/21/4/635.short
4100  - http://iv.iiarjournals.org/content/21/4/635.full
SO  - In Vivo2007 Jul 01; 21
AB  - Patented SILA compounds 409 and 421, previously shown to inhibit the efflux pumps of bacteria and cancer cells, have been studied for their ability to reduce or eliminate the presence of plasmids from Escherichia coli strains that have been induced to high level resistance to tetracycline by gradual exposure to increasing concentrations of the antibiotic. The results demonstrate that SILA compound 421, which has greater efflux pump inhibitory activity than its parent SILA compound 409, can reduce plasmid loads by 5 logs, over that present in the absence of the drug. The ability of the SILA compound to eliminate much larger plasmids is substantially lower. Because in vivo studies have shown that these compounds are not toxic to the mouse, the results obtained in our study suggest a potential role for SILA compound 421 as an adjunct for the therapy of antibiotic-resistant E. coli infections whose resistance is plasmid- mediated. In addition, because plasmid-mediated resistance is often found in tetracycline-treated cattle, SILA compound 421 may have potential as an adjunct during the time that the cattle are maintained on tetracycline prior to slaughter. Copyright © 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved